CENTERVILLE, Mass.,
Dec. 4, 2012 /PRNewswire/
-- UV Flu Technologies, Inc. (OTCBB:
UVFT) (the "Company") is pleased to announce that it has
signed a distribution agreement with the Davison Product Group,
LLC, aka DPG Distribution, of Heathrow,
Florida.
DPG is one of the country's largest distributors of high-end
retail consumer electronic products, with a client list of hundreds
of the nation's foremost retail chains. DPG sales channels also
include state and federal government, military, and online
merchants.
"We are thrilled to be working with DPG," said Jack Lennon, President of UV Flu. "DPG is one of
the nation's premier retail distributors, offering worldwide
service in sales, marketing, distribution and in-store support. We
particularly feel akin to their focus in providing the ultimate
customer experience through products of impeccable quality, and the
latest technology and innovation. DPG clients include
catalogue retailers Frontgate and Brookstone and leading retail
clients Costco, Amazon, Best Buy, QVC and countless others.
In addition to the retail contacts, DPG offers PO funding for
its manufacturing partners through Wells Fargo Bank, which will
help us ramp up our production capacity in the next quarter," said
Mr. Lennon.
Further details regarding the Company's business, acquisitions,
financial reports and agreements are filed as part of the Company's
continuous public disclosure as a reporting issuer under the
Securities Exchange Act of 1934 filed with the Securities and
Exchange Commission's ("SEC") EDGAR database. For more
information, visit: www.uvflutech.com, and click on the 5 minute
video describing the Viratech UV-400.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer; manufacturer and
distributor of bio technology products initially targeting the
rapidly growing Indoor Air Quality ("IAQ") industry sector
($7 billion in 2011). The Company
manufactures the ViraTech UV-400, which utilizes high-intensity
ultraviolet radiation (UV-C) inside a killing chamber that goes
beyond filtration to destroy harmful airborne bacteria, at rates
exceeding 99.2% on a first-pass basis, while also reducing the
concentrations of odors, and VOC's (volatile organic compounds,
such as acetone, benzene, formaldehyde, etc.) The FDA has
issued a coveted Class II medical listing that enables UV Flu
Technologies to market the product as a medical device. For more
information, visit: www.uvflutech.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that
term is defined in Section 27A of the United States Securities Act
of 1933, as amended and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements in this press release which are not
purely historical are forward-looking statements and include any
statements regarding beliefs, plans, expectations or intentions
regarding the future. Such forward-looking statements include,
among other things, the development, costs and results of new
business opportunities. Actual results could differ from those
projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the inherent
uncertainties associated with new projects and development stage
companies. These forward-looking statements are made as of the date
of this news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans,
expectations and intentions contained in this press release are
reasonable, there can be no assurance that any such beliefs, plans,
expectations or intentions will prove to be accurate. Investors
should consult all of the information set forth herein and should
also refer to the risk factors disclosure outlined in our annual
report on Form 10-K for the most recent fiscal year, our quarterly
reports on Form 10-Q and other periodic reports filed from
time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies,
Inc.
-----------------------------
John J. Lennon, President &
CEO
Investor Information:
Toll-Free: 1-877-358-5545 (FLU-KILL)
Web: www.uvflutech.com
SOURCE UV Flu Technologies, Inc.
